CK Life Sciences International (Holdings) (0775) Fundamentals 2026 — Revenue Analysis | SniperIQ
CK Life Sciences International (Holdings) (0775) is a HK-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of HK$5.6B, trading at HK$0.58 on the HKSE. This SniperIQ fundamentals page covers CK Life Sciences International (Holdings)'s valuation, profitability (net margin -3.5%), revenue (HK$5.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is CK Life Sciences International (Holdings)'s market cap?
CK Life Sciences International (Holdings) (0775) has a market capitalization of approximately HK$5.6B, trading at HK$0.58 on the HKSE. Market cap moves with the live share price.
What is CK Life Sciences International (Holdings)'s P/E ratio?
CK Life Sciences International (Holdings)'s trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is CK Life Sciences International (Holdings)?
CK Life Sciences International (Holdings) runs a net profit margin of -3.5%, a gross margin of 21.4%, and an operating margin of 2.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does CK Life Sciences International (Holdings) generate?
CK Life Sciences International (Holdings) reported revenue of HK$5.4B for fiscal year 2025, with net income of -HK
Does CK Life Sciences International (Holdings) pay a dividend?
CK Life Sciences International (Holdings) does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is CK Life Sciences International (Holdings) financially healthy?
CK Life Sciences International (Holdings) carries a debt-to-equity ratio of 1.75x and a current ratio of 0.87x, with a market beta of 0.46. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is CK Life Sciences International (Holdings) a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CK Life Sciences International (Holdings) (0775) the key facts are: market cap HK$5.6B, revenue HK$5.4B, 52-week range 0.56-1.08. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track CK Life Sciences International (Holdings)'s full fundamentals live
Get CK Life Sciences International (Holdings)'s 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.